TCM
OTLK icon

Tang Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Tang Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-400,000
Closed -$488K – 212
2025
Q1 		$488K Buy
400,000
+217,498
+119% +$381K 0.03% 183
2024
Q4 		$345K Sell
182,502
-1,377,058
-88% -$5.67M 0.02% 177
2024
Q3 		$8.33M Sell
1,559,560
-59,852
-4% -$438K 0.59% 49
2024
Q2 		$12M Hold
1,619,412
– – 1.22% 27
2024
Q1 		$19.3M Buy
+1,619,412
New +$13.1M 2.01% 12

Other funds holding OTLK

SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tang Capital Management's OTLK Position: Q2 2025 in Review

Tang Capital Management sold out of Outlook Therapeutics (OTLK) in Q2 2025, closing a stake of 400,000 shares — an estimated $488K sold.

Tang Capital Management first reported a position in OTLK in Q1 2024 and held it in 5 quarters. The position peaked at $19.3M in Q1 2024. 66 funds tracked by Wall St. Rank hold OTLK as of Q2 2025.

  • Tang Capital Management reported no remaining Outlook Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Tang Capital Management sold 400,000 Outlook Therapeutics shares in Q2 2025, an estimated $488K.
  • Tang Capital Management first reported a position in Outlook Therapeutics in Q1 2024 and held it in 5 quarters.
  • Tang Capital Management's Outlook Therapeutics position peaked at $19.3M in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2025.

Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.